Mainland China, Taiwan, and Hong Kong each offer a distinct entry profile. Picking the right first filing — and the right sequence — has more impact on your Asia P&L than most teams realise.
For most MedTech innovators, "Asia" is not a single decision — it is a sequence of three: Hong Kong (HKMDD), Taiwan (TFDA), and mainland China (NMPA). Each authority has its own dossier expectations, in-country representation rules, and commercial logic. Picking the wrong first filing, or the wrong order, can quietly cost a year of revenue.
This article puts the three side by side and offers a sequencing framework you can defend in front of a board.
The three regimes at a glance
HKMDD — Hong Kong
- Status: Voluntary listing, but expected by hospitals and tenders.
- Timeline: 4–9 months for Class II/III with reference approval.
- Local representation: Local Responsible Person (LRP) required from Class II.
- Best for: Validation, APAC credibility, English-language dossier reuse.
TFDA — Taiwan
- Status: Mandatory pre-market approval. Predictable, well-documented process.
- Timeline: 6–14 months depending on class and QMS audit needs.
- Local representation: In-country license holder required.
- Best for: Mid-sized but mature market with strong reimbursement and clinical sophistication.
NMPA — Mainland China
- Status: Mandatory. The most demanding of the three.
- Timeline: 18–36 months for Class II/III, including mandatory type testing at a recognised Chinese lab and, often, local clinical data.
- Local representation: Chinese legal agent required; technical file in simplified Chinese.
- Best for: The market itself — by far the largest medical device market in Asia.
Cost shape
HKMDD and TFDA are dossier-and-fee regimes; NMPA is a dossier-fee-plus-test-plus-clinical regime. That changes both the cash profile and the project plan.
A useful rule of thumb: HKMDD will cost low five figures, TFDA mid five figures, NMPA mid-six figures and up once type testing and local clinicals are in. Plan capital accordingly.
How to sequence
There is no single right answer, but three patterns dominate in our work with MedTech innovators:
- HK → TW → CN. Use Hong Kong to validate the proposition, generate Asia clinical experience, and build a credible KOL story. File TFDA in parallel once HK is in motion. Begin NMPA work as the commercial thesis hardens.
- HK + CN in parallel. If China is the strategic prize and capital is available, start NMPA early because it is the longest critical path. HK keeps near-term revenue alive.
- TW first, HK opportunistically. For devices where Taiwan is the natural lead market (e.g. certain reimbursed categories), file TFDA first and add HKMDD when a hospital opportunity demands it.
The sequencing trap
The expensive mistake is filing all three at once with the same generic dossier. Each authority asks for the evidence to be framed differently — clinical evaluations, risk files, labelling, and post-market plans need to be tuned, not photocopied. A unified Asia regulatory strategy that maps the same underlying evidence into three jurisdiction-specific stories is what compresses time without compromising quality.
What to do next
Before committing capital, run a 90-minute strategy session that overlays your commercial plan (where do the first 50, then 500, hospital accounts realistically come from?) against the three regulatory clocks. The output should be a one-page sequencing decision with a named in-country representative for each market in scope.
